Ezetimibe Treatment of Pediatric Patients with Hypercholesterolemia

Journal of Pediatrics

Volumn 154, Issue 6, 2009, Pages 869-872

  Clauss, Sarah ^a   Wai, Kit Man ^a   Kavey, Rae Ellen W ^a   Kuehl, Karen ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHILD; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA, FAMILIAL COMBINED; MALE; TRIGLYCERIDES;

EID: 67349114289     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2008.12.044     Document Type: Article

References (17)

1. Berenson G.S., Srinivasan S.R., Bao W., Newman III W.P., Tracy R.E., and WA W. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults; the Bogalusa Heart Study. N Engl J Med 338 (1998) 1650-1656
2. Strong J.P., and McGill Jr. H.C. The natural history of aortic atherosclerosis: relationship to race, sex and coronary lesions in New Orleans. Exp Mol Pathol 52 (1963) 1-27
3. Strong J.P., and McGill Jr. H.C. The natural history of coronary atherosclerosis. Am J Pathol 40 (1962) 37-49
4. Bao W., Srinivasan S.R., Wattigney W.A., Bao W., and Berenson G.S. Usefulness of childhood low-density lipoprotein cholesterol level in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Arch Int Med 156 (1996) 1315-1320
5. Srinivasan S.R., Frontini M.G., Xu J., and Berenson G.S. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Pediatrics 118 (1996) 201-206
6. American Academy of Pediatrics. National Cholesterol Education Program: report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89 (1992) 525-584
7. Dujovne C.A., Ettinger M.P., McNeer J.F., Lipka L.J., LeBeaut A.P., Suresh R., et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90 (2002) 1092-1097
8. Bays H.E., Moore P.B., Drehobl M.A., Rosenblatt S., Toth P.D., Dujovne C.A., et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 23 (2001) 1209-1230
9. Ballantyne C. Ezetimibe: efficacy and safety in clinical trials. Eur Heart J 90 (2002) 1084-1091
10. Kosoglou T., Kakker T., Statkevich P., Anderson L., Pai S., Boutros T., et al. Multiple-dose safety and pharmoacokinetics of ezetimibe in adolescent children (abstract). Clin Pharmacol Ther 69 (2001) 52
11. McCrindle B.W., Urbina E.M., Dennison B.A., Jacobson M.S., Steinberger J., Rocchini A.P., et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in Young, with the Council on Cardiovascular Nursing. Circulation 115 (2006) 1948-1967
12. Slim H., and Thompson P. Ezetimbe-related myopathy-a systematic review. J Lipidol 2 (2008) 328-334
13. Sweeney M.E., and Johnson R.R. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 3 (2007) 441-450
14. Knopp R.H., Gitter H., Truitt T., Bays H., Manion C.V., Lipka L.J., et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24 (2003) 729-741
15. van Heek M., Austin T.M., Farley C., Cook J.A., Tetzloff G.G., and Davis H.R. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes 50 (2001) 1330-1335
16. van Heek M., Farley C., Compton D.S., Hoos L.Z., Smith-Torhan A., and Davis H.R. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol 138 (2003) 1459-1464
17. Kastelein J.J.P., Akdim F., Stroes E.S.G., Zwinderman A.H., Bots M.L., Stalenhof A.F.H., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443